Answers are grounded in this paper and cite their sources.
Vaccine development using recombinant pseudorabies virus shows effective immune response in mice, indicating potential for disease prevention.
Nipah virus disease, caused by Nipah virus (NiV), is a zoonotic infectious disease with an extremely high fatality rate. Owing to the absence of effective countermeasures, Nipah virus disease has caused substantial economic losses in the swine farming industry. Vaccines represent the most cost-effective approach for prevention and control. Herein, we describe the development of a recombinant pseudorabies virus (PRV)-vectored vaccine (designated PRV-HNX-ΔTK/gE-NiV-G), which expresses the codon-optimized full-length glycoprotein of Nipah virus (NiV-G). The biological characteristics of this strain, including plaque morphology, growth kinetics, and genetic stability, were evaluated in vitro. Furthermore, the recombinant virus exhibited favorable safety profiles in mice. Intramuscular administration of PRV-HNX-ΔTK/gE-NiV-G elicited high-titer neutralizing antibodies against NiV-G and a robust cellular immune response in BALB/c mice. Taken together, these findings indicate that PRV-HNX-ΔTK/gE-NiV-G has potential as a promising candidate for the development of bivalent vaccines that target both NiV and PRV infections.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: